Below are the most recent publications written about "tau Proteins" by people in Profiles.
-
Koops EA, Giudicessi A, Baena A, Martinez L, Bonillas-Felix N, Medrano R, Dutta J, Gonzalez I, Alvarez S, Aguillon D, Quiroz YT, Jacobs HIL. Vulnerability of the locus coeruleus-entorhinal cortex white matter tract in autosomal dominant Alzheimer's disease. Alzheimers Dement. 2026 Jun; 22(6):e71587.
-
Jiang X, Hoang TD, Shaw LM, Jacobs DR, Nasrallah IM, Bryan RN, Yaffe K. Alzheimer's disease neuropathology plasma biomarkers and cognition in midlife: a community-based cohort study. Lancet. 2026 May 30; 407(10544):2208-2216.
-
Robinson TL, Montenegro GDC, Fu JF, Pintucci EN, Properzi MJ, Penney DL, Davis R, Sperling RA, Johnson KA, Amariglio RE, Rentz DM. Digital maze test reveals cognitive performance patterns associated with amyloid-? and tau. Neuropsychology. 2026 Jul; 40(5):465-475.
-
Carbone E, Zingaropoli MA, Perrone F, Talarico G, Pasculli P, Minni A, Petrella C, Barbato C, Piscopo P. Profile of Tau-Associated Selected MicroRNAs in Hospitalized COVID-19 Patients: An Exploratory Single-Center Study. Cells. 2026 Mar 12; 15(6).
-
Petersen KK, Mil?-Alom? M, Li Y, Du L, Xiong C, Tosun D, Saef B, Saad ZS, Du-Cuny L, Coomaraswamy J, Mordashova Y, Rubel CE, Meyers EA, Shaw LM, Dage JL, Ashton NJ, Zetterberg H, Ferber K, Triana-Baltzer G, Baratta M, Rosenbaugh EG, Cruchaga C, McDade E, Holtzman DM, Morris JC, Sabandal JM, Bateman RJ, Bannon AW, Potter WZ, Schindler SE. Predicting onset of symptomatic Alzheimer's disease with plasma p-tau217 clocks. Nat Med. 2026 Mar; 32(3):1085-1094.
-
Zhang B, McEvoy LK, Nguyen S, Espeland MA, Rapp SR, Horvath S, Lu AT, LaCroix AZ, Nievergelt CM, Maihofer AX, Resnick SM, Mielke MM, Beckman K, Li D, Silver B, Manson JE, Ferrucci L, Shadyab AH. Epigenetic clocks and longitudinal plasma biomarkers of Alzheimer's disease. Alzheimers Dement. 2025 12; 21(12):e70983.
-
Cousins KAQ, Korecka M, Wan Y, Vulaj A, Brown C, Tropea TF, Lee EB, Tosun D, Landau SM, Okonkwo OC, Mindt MR, Weiner MW, Irwin DJ, Wolk DA, Shaw LM. Comparison of plasma p-tau217/A?42, p-tau217, and A?42/A?40 biomarkers by race to detect Alzheimer's disease. Alzheimers Dement. 2025 Aug; 21(8):e70469.
-
Davis SM, Hildebrand S, MacMillan HJ, Monopoli KR, Buchwald J, Sousa J, Cooper D, Ly S, Echeverria D, McHugh N, Ferguson C, Coles A, Hariharan VN, O'Reilly D, Tang Q, Furgal R, Yamada K, Alterman JF, Gilbert JW, Knox E, Pineda Y, Weston CN, Baer CE, Pai AA, Khvorova A. Systematic analysis of siRNA and mRNA features impacting fully chemically modified siRNA efficacy. Nucleic Acids Res. 2025 Jun 20; 53(12).
-
Mil?-Alom? M, Tosun D, Schindler SE, Hausle I, Petersen KK, Li Y, Dage JL, Du-Cuny L, Saad ZS, Saef B, Triana-Baltzer G, Raunig DL, Coomaraswamy J, Baratta M, Meyers EA, Mordashova Y, Rubel CE, Ferber K, Kolb H, Ashton NJ, Zetterberg H, Rosenbaugh EG, Sabandal M, Shaw LM, Bannon AW, Potter WZ. Timing of Changes in Alzheimer's Disease Plasma Biomarkers as Assessed by Amyloid and Tau PET Clocks. Ann Neurol. 2025 09; 98(3):508-523.
-
Duong MT, Das SR, Khandelwal P, Lyu X, Xie L, McGrew E, Dehghani N, McMillan CT, Lee EB, Shaw LM, Yushkevich PA, Wolk DA, Nasrallah IM. Hypometabolic mismatch with atrophy and tau pathology in mixed Alzheimer's and Lewy body disease. Brain. 2025 May 13; 148(5):1577-1587.